Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions

Elizabeth Cairns

Senior biopharma journalist

Roche is in discussions with the US administration on drug pricing, but CEO Thomas Schinecker declined to say whether it might strike a deal similar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Are recent strides in neurology R&D enough to make it a hot M&A target?

FDA brings GSK's Blenrep back to the market in multiple myeloma

Post-Hoc: Why we tracked pharma’s private jet flights to DC

Inhibrx will head to FDA for bone cancer drug next year after strong data

Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchise

The advent of digital therapeutics and what it means for healthcare

Roche in talks with US on drug pric­ing, sets out pipeline and deal­mak­ing am­bi­tions

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Are re­cent strides in neu­rol­o­gy R&D enough to make it a hot M&A tar­get?

FDA brings GSK's Blenrep back to the mar­ket in mul­ti­ple myelo­ma

Post-Hoc: Why we tracked phar­ma’s pri­vate jet flights to DC

In­hi­brx will head to FDA for bone can­cer drug next year af­ter strong da­ta

Sanofi’s Dupix­ent sales con­tin­ue to de­liv­er as ‘neg­a­tive buzz’ im­pacts vac­cine fran­chise

The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions

Are recent strides in neurology R&D enough to make it a hot M&A target?

FDA brings GSK's Blenrep back to the market in multiple myeloma

Post-Hoc: Why we tracked pharma’s private jet flights to DC

Inhibrx will head to FDA for bone cancer drug next year after strong data

Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchise

The advent of digital therapeutics and what it means for healthcare